- Home
- CLLS vs LUNG Comparison
CLLS vs LUNG Comparison
Compare CLLS & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CLLS | LUNG |
|---|---|---|
| Founded | 1999 | 1995 |
| Country | France | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Specialties |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 299.0M | 63.6M |
| IPO Year | 2007 | 2020 |
Fundamental Metrics
Financial Performance| Metric | CLLS | LUNG |
|---|---|---|
| Price | $4.40 | $2.51 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 7 |
| Target Price | ★ $8.00 | $6.81 |
| AVG Volume (30 Days) | 133.9K | ★ 1.1M |
| Earning Date | 11-07-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $82,551,000.00 | ★ $91,664,000.00 |
| Revenue This Year | $32.58 | $9.21 |
| Revenue Next Year | N/A | $5.03 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 129.04 | 15.59 |
| 52 Week Low | $1.10 | $1.31 |
| 52 Week High | $5.48 | $9.37 |
Technical Indicators
Market Signals| Indicator | CLLS | LUNG |
|---|---|---|
| Relative Strength Index (RSI) | 49.34 | 69.75 |
| Support Level | $4.47 | $2.43 |
| Resistance Level | $5.45 | $2.65 |
| Average True Range (ATR) | 0.30 | 0.21 |
| MACD | -0.12 | 0.05 |
| Stochastic Oscillator | 31.17 | 92.13 |
Price Performance
Historical ComparisonAbout CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.
About LUNG Pulmonx Corporation
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.